Personalized Search
Displaying 61 - 80 of 463
The recently-approved hypomethylating treatment, Inoqvi, is a daily oral version of two IV or subcutaneous medications. Listen to Dr. Amer Zeidan of Yale Cancer Center explain which MDS patients could qualify, and what it means for their treatment at the link.
Podcast Episode last updated
.
Node ID (debugging only): 1252
Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.
Podcast Episode last updated
.
Node ID (debugging only): 1249
Nancy has worked with hundreds of patients in her career, guiding patients through decision-making and treatment. Discover her best advice for
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal…
Podcast Episode last updated
.
Node ID (debugging only): 1230
Can sleep affect your treatment for
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be…
diseases? Dr.…
Podcast Episode last updated
.
Node ID (debugging only): 1231
Listen to Duane's story, leading to his 2009 transplant, and continuing survivorship!
Podcast Episode last updated
.
Node ID (debugging only): 1228
Patrice banned "stinkin' thinkin'" from her mind as she began treatment for aplastic
anemia
anemia:
(uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count. Symptoms of anemia are fatigue and tiredness.
. Later, she'd continue that practice during her
bone marrow transplant
bone marrow transplant…
Podcast Episode last updated
.
Node ID (debugging only): 1229
"Never give up!" That's Brandi's advice to patients. Her diagnosis was months in coming, and then more time to find the best allogenic donor for her transplant---over 19 months in the hospital between diagnosis and successful transplant.
Podcast Episode last updated
.
Node ID (debugging only): 1226
"Three hours after they drew my blood, my doctor called to tell me to go immediately to the emergency room!" Because Kirollos was a pharmacy student, he understood that having such low blood counts needed fast treatment, but he was still surprised. Discover how he progressed from diagnosis to transplant to survivorship quickly here.
Podcast Episode last updated
.
Node ID (debugging only): 1227
Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, which led to the recent FDA approval of abatacept for the prevention of acute graft-vs-host disease (GVHD) in adult and pediatric patients. The data suggest improved overall survival with the…
Article last updated
.
Node ID (debugging only): 1485
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3
chemotherapy
chemotherapy:
(kee-moe-THER-uh-pee) The use of medicines that kill cells (cytotoxic agents). People with high-risk or intermediate-2 risk myelodysplastic syndrome (MDS) may be given chemotherapy to kill bone marrow cells that have an abnormal size, shape, or look. Chemotherapy hurts…
Article last updated
.
Node ID (debugging only): 1340
Pevonedistat plus
azacitidine
azacitidine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U…
increased overall survival, event-free…
Article last updated
.
Node ID (debugging only): 1365
The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy.
The FDA has granted a fast track designation for aspacytarabine (BST-236) as treatment for
acute myeloid leukemia
acute myeloid leukemia:
(uh-…
Article last updated
.
Node ID (debugging only): 1371
In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to…
Article last updated
.
Node ID (debugging only): 1376
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received
venetoclax
venetoclax:
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
/…
Article last updated
.
Node ID (debugging only): 1381
VIDEO
Description:
Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo.
When it comes to
Acute Myeloid Leukemia
Acute Myeloid Leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the…
Article last updated
.
Node ID (debugging only): 1382
Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature.…
Article last updated
.
Node ID (debugging only): 1388
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone…
Article last updated
.
Node ID (debugging only): 1411
Treatment with the oral agent showed sustained health-related quality of life compared with
placebo
placebo:
A placebo is an inactive pill, liquid, or powder that has no treatment value.
in patients with
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the…
Article last updated
.
Node ID (debugging only): 1396
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/refractory FLT3-positive
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of…
Article last updated
.
Node ID (debugging only): 1417
Ivosidenib
Ivosidenib:
A small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer, including acute myeloid leukemia (AML).
, an inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, was well tolerated and associated with deep and durable responses in combination with
azacitidine
azacitidine:
It works by reducing…
Article last updated
.
Node ID (debugging only): 1412